Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Despite Kudlow's expectations, China said on Saturday that it strongly opposes Trump's decision to levy additional tariffs on $550 billion worth of Chinese goods, and warned...Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Focusing on developing targeted therapeutics, Endocyte expands Novartis' platform with "both a potential near-term product launch and early-stage clinical development programs," Novartis said in a press release.
Novartis also raised its full-year sales outlook, citing growing revenue from its Cosentyx psoriasis and arthritis drug as well as the performance of its heart failure medicine Entresto, whose third-quarter sales more than doubled.
Novartis now expects sales to grow in the mid-single-digit percentage range at constant currencies, up from its previous forecast of low-to-mid-single-digit percentage rates.
Shares of Novartis were over 1.5 percent higher during mid-morning deals on Thursday.
"We are very pleased with how the innovative medicines business is performing, we are seeing strong growth on our key growth drivers Entresto and Cosentyx as well as across our oncology portfolio," Vasant Narasimhan, CEO of Novartis, told CNBC's "Squawk Box Europe" on Thursday.
Third-quarter core net income rose 2 percent to $3.1 billion, compared to the average analyst forecast of $3 billion in a Reuters poll. Sales rose 3 percent to $12.78 billion, compared to the average forecast of $12.84 billion in the poll.
"I think we really have to show investors that we have the innovation power to grow. ... And I think investors understandably for a period of time were questioning whether that innovation power is there," Narasimhan said.
"I hope we are starting to demonstrate through the work we are doing in these platforms, the other filings that we announced today that we have that innovation power to drive growth — and that will ultimately be reflected in our valuation."
— Reuters contributed to this report.